Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Viridian Therapeutics, Inc. (VRDN) had Debt to Capital Ratio of 0.06 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$70.85M |
|
$-342.60M |
|
-- |
|
$70.85M |
|
$434.24M |
|
$-363.39M |
|
$20.79M |
|
$-342.60M |
|
$-342.60M |
|
$-342.60M |
|
$-342.60M |
|
$-342.60M |
|
$-342.60M |
|
$-363.39M |
|
$-369.69M |
|
84.80M |
|
84.80M |
|
$-3.32 |
|
$-3.32 |
|
| Balance Sheet Financials | |
$894.23M |
|
$1.23M |
|
$5.18M |
|
$899.42M |
|
$70.70M |
|
$49.94M |
|
$106.56M |
|
$177.25M |
|
$590.11M |
|
$722.17M |
|
$722.17M |
|
101.83M |
|
| Cash Flow Statement Financials | |
$-276.39M |
|
$-37.56M |
|
$426.74M |
|
$99.59M |
|
$212.38M |
|
$112.79M |
|
$44.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.65 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.06 |
0.07 |
|
100.00% |
|
-512.91% |
|
-512.91% |
|
-521.80% |
|
-483.56% |
|
-483.57% |
|
$-276.89M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
-- |
|
-- |
|
-58.06% |
|
-47.44% |
|
-38.09% |
|
-44.37% |
|
$7.09 |
|
$-3.27 |
|
$-3.26 |
|